Trial Profile
A Phase 2 Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Sargramostim
- Indications Cancer metastases; Osteosarcoma
- Focus Therapeutic Use
- 04 Oct 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Results published in the European Journal of Cancer
- 31 May 2020 According to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology, protocol was revised to allow only the 4-day schedule because one patient receiving the 2-day schedule died after cycle 2 due to an unknown cause.